Zacks Investment Management 13F: Cuts ABT Stake by $12M

Zacks Cuts Stake in Abbott Laboratories

Zacks Investment Management has reduced its stake in Abbott Laboratories (NYSE: ABT) by 125,015 shares, which is a 25.8% decrease, leaving it with 358,701 shares valued at approximately $33.4 million. This adjustment reflects the fund's position as of May 14, 2026, according to the latest Form 13F filing with the SEC.

Understanding the Position Change

Zacks Investment Management's decision to cut its holdings comes after it previously held 483,716 shares. This reduction indicates a strategic shift in its investment approach, possibly in response to market conditions or company performance.

Institutional Activity Around Abbott

While there are no other funds reported as peers in this filing, it's worth noting that other institutions have been active with Abbott's stock recently. For example, on May 15, 2026, the Canada Pension Plan Investment Board increased its stake by 691,435 shares, reflecting a 36% growth in its holdings. This activity suggests a mixed sentiment among institutional investors regarding Abbott's future prospects.

Stock Performance Context

Abbott Laboratories is currently trading at $93.06, a significant distance from its 52-week high of $132.03 and above its low of $81.97. The stock has seen fluctuations that may have influenced Zacks' decision to reduce its position. Investors might find the stock's current pricing relevant as it sits below its 50-day moving average of $105.93.

Analysts Set New Price Targets

Analysts continue to show confidence in Abbott Laboratories. On October 16, 2026, TD Cowen reiterated its Buy rating with a price target of $135. Barclays initiated coverage on October 7, 2026, with an Overweight rating and a target of $120. Rothschild & Co upgraded its rating to Buy on October 2, 2026, with a target of $127. Overall, analysts have a strong buy consensus on the stock, reflected in a mean price target of $120.71 based on 26 opinions.

What Abbott Laboratories Does

Abbott Laboratories, based in Abbott Park, Illinois, is a global healthcare company that develops and sells a wide variety of healthcare products, including medical devices, nutritional products, and diagnostics. The company's strong portfolio positions it well within the healthcare sector, which is crucial for long-term growth.

What's Ahead for Abbott Laboratories

Investors will be watching for Abbott's next earnings report, scheduled for October 21, 2026. It's important to note that the recent 13F filing reflects past holdings and may not represent the current position of Zacks Investment Management. As institutional trading continues, market watchers will keep an eye on how these changes affect Abbott's stock performance in the coming months.